Predicting clinical outcomes in chordoma patients receiving immunotherapy: A comparison between volumetric segmentation and RECIST
Số trang: 9
Loại file: pdf
Dung lượng: 2.23 MB
Lượt xem: 10
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The Response Evaluation Criteria in Solid Tumors (RECIST) are the current standard for evaluating disease progression or therapy response in patients with solid tumors. RECIST 1.1 calls for axial, longest-diameter (or perpendicular short axis of lymph nodes) measurements of a maximum of five tumors, which limits clinicians’ ability to adequately measure disease burden, especially in patients with irregularly shaped tumors.
Nội dung trích xuất từ tài liệu:
Predicting clinical outcomes in chordoma patients receiving immunotherapy: A comparison between volumetric segmentation and RECIST
Nội dung trích xuất từ tài liệu:
Predicting clinical outcomes in chordoma patients receiving immunotherapy: A comparison between volumetric segmentation and RECIST
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Response criteria Evaluating disease progression Therapy response Solid tumors Perpendicular short axisGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 169 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 110 0 0 -
12 trang 88 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 37 0 0
-
11 trang 35 0 0
-
12 trang 34 0 0